Document is current

Article History

Received: 24 August 2023

Revised: 18 September 2023

Accepted: 19 September 2023

First Online: 3 November 2023

Declarations

:

: Bernhard Neumann reports no disclosures; Klemens Angstwurm reports travel support (until 2014) from Alexion, Bayer, BiogenIdec, MerckSerono, Novartis, Teva and honoria from Biogen und TEVA; moreover he has been principal investigatore in studies in neuroimmunology sponsored by Alexion, Bayer, Biogen, Chugay, MerckSerono, Novartis, and Roche; all not related to the present study; Christian Dohmen reports no disclosures; Philipp Mergenthaler is on the Advisory Board of HealthNextGen Inc. and has equity interest in the company, within the scope of the present work, but not directly related; Siegfried Kohler reports no disclosures; Silvia Schönenberger reports no disclosures; De-Hyung Lee reports no disclosures; Stefan T. Gerner reports no disclosures; Hagen B. Huttner reports personal fees from Daiichi Sanyko, grants and personal fees from Novartis, grants and personal fees from UCB Pharma, grants and personal fees from Portola Pharmaceuticals, personal fees from Bayer AG, personal fees from Boehringer Ingelheim, personal fees from Prediction BioSciences, outside the submitted work; Andrea Thieme reports no disclosures; Andreas Steinbrecher reports no disclosures; Juliane Dunkel reports no disclosures; Christian Roth reports no disclosures; Hauke Schneider reports no disclosures; Heinz Reichmann reports no disclosures; Hannah Fuhrer reports no disclosures; Ingo Kleiter reports personal fees from Biogen, personal fees from Novartis, personal fees from Merck, personal fees from Sanofi Genzyme, personal fees from Roche, personal fees from Mylan, personal fees from Alexion, personal fees from Celgene, grants and personal fees from Chugai, personal fees from IQVIA, outside the submitted work; Christiane Schneider-Gold has received speaker ‘s and consulting honoraria from Alexion Pharmaceuticals, Amicus Therapeutics, Argenx, Bayer Vital, Hormosan Pharma, Immunovant, Janssen, Lupin Pharmaceuticals, Roche, Sanofi-Genzyme, Teva (2017) and UCB Pharma. Travel grant from Alexion. All outside the submitted work; Anke Alberty reports no disclosures; Jan Zinke reports no disclosures; Michael Schroeter reports personal fees from Alexion, Argenx, Bayer, Biogen, Datamed, Gilead, Grifols, Merck, Novartis, Roche, Sanofi, Teva, UCB outside the submitted work.; Ralf Linker reports no disclosures; Andreas Meisel reports financial research support (paid to his institution) and personal fees from Alexion, AstraZeneca Rare Disease, financial research support (paid to his institution) and personal fees from argenx, personal fees from Grifols, personal fees from Hormosan, personal fees from Janssen, personal fees from Merck, personal fees from Novartis, financial research support (paid to his institution) from Octapharma, personal fees from UCB, outside the submitted work. He is chairman of the medical advisory board of the German Myasthenia Gravis Society; Julian Bösel reports personal fees from Medtronic, personal fees from Zoll, personal fees from Boehringer Ingelheim, personal fees from Sedana Medical, personal fees from PCORI outside the submitted work; Henning R Stetefeld reports no disclosures. Statistical Analysis conducted by Dr. Bernhard Neumann, University Medical Center Regensburg/Donau-Isar-Klinikum Deggendorf. The authors declare no financial or other conflicts of interest related to the manuscript.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local ethic committees and institutional review boards of the participating centers approved the study based on the central vote of the ethics committee at University of Regensburg (No: 15-101-0259). Due to the retrospective character of the study patient’s consent was not necessary according to the decisions of the ethic committees and institutional review boards.